Abstract
Micafungin is an echinocandin-class antifungal agent licensed for treatment of invasive disease in adults. The optimal dosing regimens have not been established for infants. We describe a premature infant who developed hepatitis and cholestasis during micafungin therapy initiated for protracted candidemia. Practitioners should be aware of this potential adverse effect if using micafungin in young patients.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
AIDS-Related Opportunistic Infections / drug therapy*
-
Alanine Transaminase / blood
-
Amphotericin B / administration & dosage
-
Amphotericin B / adverse effects
-
Antifungal Agents / administration & dosage
-
Antifungal Agents / adverse effects*
-
Aspartate Aminotransferases / blood
-
Candidiasis / drug therapy*
-
Chemical and Drug Induced Liver Injury / diagnosis
-
Chemical and Drug Induced Liver Injury / etiology*
-
Cholestasis / chemically induced
-
Cholestasis / diagnosis
-
Dose-Response Relationship, Drug
-
Drug Therapy, Combination
-
Echinocandins / administration & dosage
-
Echinocandins / adverse effects*
-
Female
-
Fungemia / drug therapy*
-
Humans
-
Infant
-
Infant, Newborn
-
Infant, Premature, Diseases / drug therapy*
-
Lipopeptides / administration & dosage
-
Lipopeptides / adverse effects*
-
Liver Function Tests
-
Micafungin
Substances
-
Antifungal Agents
-
Echinocandins
-
Lipopeptides
-
Amphotericin B
-
Aspartate Aminotransferases
-
Alanine Transaminase
-
Micafungin